What does GLS — total diversified reinsurance adverse PPD mean?

This metric represents the total unfavorable prior period development (PPD) recognized within the diversified reinsurance portfolio. It reflects the additional costs incurred when actual claims experience exceeds the initial loss reserves established in previous reporting periods. Monitoring this helps investors assess the accuracy of historical underwriting assumptions and the potential for future earnings volatility.

King Pharmaceuticals KG GLS — Total Diversified Reinsurance adverse PPD

Other product segments

International

$824K—

AmTrust Quota Share

-$370K—

LPT/ADC Agreement

-$179K—

European Hospital Liability Quota Share

-$2K—

Similar metrics at other companies

CBGlobal Reinsurance Non Casualty — Short-Duration PPD

-$5.25M+25.0%

CBGlobal Reinsurance Casualty — Short-Duration PPD

-$2.25M-213%

CBSegment Global Reinsurance — Other PPD adjustments

$0+100%

CBOverseas General Non Casualty — Short-Duration PPD

-$82.25M-26.1%

CBOverseas General Casualty — Short-Duration PPD

-$16.25M+36.3%

CBSegment Insurance Overseas General — Other PPD adjustments

-$32M-4,167%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:LiabilityforUnpaidClaimsandClaimsAdjustmentExpensePeriodIncreaseDecreaseNetofCommissionChanges.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's gls — total diversified reinsurance adverse ppd.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's GLS — total diversified reinsurance adverse PPD?: King Pharmaceuticals (KG) reported GLS — total diversified reinsurance adverse PPD of $65.5K in Q4 2025.
What does GLS — total diversified reinsurance adverse PPD mean?: This metric represents the total unfavorable prior period development (PPD) recognized within the diversified reinsurance portfolio. It reflects the additional costs incurred when actual claims experience exceeds the initial loss reserves established in previous reporting periods. Monitoring this helps investors assess the accuracy of historical underwriting assumptions and the potential for future earnings volatility.